Seven Eight Capital, LP Alkermes Plc. Transaction History

Seven Eight Capital, LP

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$28.34 - $33.63 $160,546 - $190,513	-5,665 Reduced 37.38%	9,491 $297,000
Q1 2023 May 12, 2023	BUY	$25.31 - $29.02 $383,598 - $439,827	15,156 New	15,156 $427,000
Q4 2021 Feb 14, 2022	SELL	$21.47 - $32.08 $2.04 Million - $3.04 Million	-94,885 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$23.37 - $32.13 $341,061 - $468,905	14,594 Added 18.18%	94,885 $2.93 Million
Q2 2021 Aug 13, 2021	BUY	$18.78 - $25.15 $1.18 Million - $1.57 Million	62,603 Added 353.93%	80,291 $1.97 Million
Q4 2020 Feb 09, 2021	BUY	$15.39 - $22.1 $272,218 - $390,904	17,688 New	17,688 $353,000
Q2 2020 Aug 06, 2020	SELL	$13.31 - $19.41 $173,030 - $252,330	-13,000 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$13.06 - $21.24 $194,267 - $315,945	-14,875 Reduced 53.36%	13,000 $187,000
Q4 2019 Feb 13, 2020	BUY	$17.29 - $21.74 $481,958 - $606,002	27,875 New	27,875 $569,000
Q3 2019 Nov 14, 2019	SELL	$19.51 - $24.28 $1.82 Million - $2.26 Million	-93,075 Closed	0 $0
Q2 2019 Aug 12, 2019	BUY	$21.47 - $37.33 $827,604 - $1.44 Million	38,547 Added 70.69%	93,075 $2.1 Million
Q1 2019 May 15, 2019	BUY	$28.4 - $36.49 $1.55 Million - $1.99 Million	54,528 New	54,528 $1.99 Million
Q4 2018 Feb 14, 2019	SELL	$27.94 - $44.61 $425,470 - $679,321	-15,228 Closed	0 $0
Q3 2018 Oct 18, 2018	BUY	$38.6 - $46.12 $587,800 - $702,315	15,228 New	15,228 $646,000
Q2 2018 Aug 07, 2018	SELL	$40.56 - $51.36 $2.38 Million - $3.02 Million	-58,781 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$53.61 - $67.26 $3.15 Million - $3.95 Million	58,781 New	58,781 $3.41 Million

362

181M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.88B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Seven Eight Capital, LP with notifications on news.